Assessment of CYP1A2 enzyme activity in relation to type-2 diabetes and habitual caffeine intake

Nutrition and Metabolism

Volumn 13, Issue 1, 2016, Pages 1-9

  Urry, Emily ^a,b   Jetter, Alexander ^c   Landolt, Hans Peter ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Caffeine; HPLC; Paraxanthine; Phenotyping

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; INSULIN; ORAL CONTRACEPTIVE AGENT; PARAXANTHINE;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CONTROLLED STUDY; CYP1A2 GENE; DEMETHYLATION; DISEASE ASSOCIATION; DNA POLYMORPHISM; EATING HABIT; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE INDUCTION; HUMAN; IMMUNOREACTIVITY; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PURINE METABOLISM; SALIVA LEVEL; SEX DIFFERENCE; SMOKING;

EID: 84992073940     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/s12986-016-0126-6     Document Type: Article

References (32)

1. Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics. 1992;2(2):73-7.
2. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol. 2005;97:125-34.
3. Schrenk D, Brockmeier D, Mörike K, Bock KW, Eichelbaum M. A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur J Clin Pharmacol. 1998;53:361-7.
4. Tantcheva-Poór I, Zaigler M, Rietbrock S, Fuhr U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics. 1999;9(2):131-44.
5. Barnett CR, Wilson J, Wolf CR, Flatt PR, Ioannides C. Hyperinsulinemia causes a preferential increase in hepatic P4501A2 activity. Biochem Pharmacol. 1992;43(6):1255-61.
6. Hong CC, Tang BK, Hammond GL, Tritchler D, Yaffe M, Boyd NF. Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6:R352-65.
7. Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, Garner RC, Boobis AR, Wolf CR, Gooderham NJ. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol. 2003;55:68-76.
8. Sachse C, Brockmöller J, Bauer S, Roots I. Functional significance of a C to A polymorphism in intron 1 of the CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999;47(4):445-9.
9. Fuhr U, Rost KL, Engelhardt R. Evaluation of caffeine as a test drug for CYP1A2. NAT2 and CYP2E1 phenotyping in man in vivo versus in vitro correlations. Pharmacogenetics. 1996;6:159-76.
10. Streetman DS, Bertino Jr JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000;10:187-216.
11. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and saliva. Pharmacogenetics. 1994;4:109-16.
12. Urry E, Jetter A, Holst SC, Berger W, Spinas GA, Langhans W, Landolt HP. Relationships among type 2 diabetes, sleepiness, and habitual caffeine intake: a case-control field study. J Psychopharmacol. 2016. In press. doi:10.1177/0269881116668595.
13. Matzke GR, Reginald FF, John JE, Robert JS, Stanley WC. Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy. 2000;20(2):182-90.
14. Spigset O, Hägg S, Söderström E, Dahlqvist R. The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? Pharmacogenetics. 1999;9:409-12.
15. Rétey JV, Adam M, Khatami R, et al. Genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. Clin Pharmacol Ther. 2007;81:692-8.
16. Han XM, Ou-Yang DS, Lu PX, et al. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics. 2001;11(5):429-35.
17. Perera V, Gross AS, McLachlan AJ. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. Biomed Chromatogr. 2010;24:1136-44.
18. Perera V, Gross AS, Xu H, McLachlan AJ. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. J Pharm Pharmacol. 2011;63:1161-8.
19. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther. 1983;33:591-602.
20. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther. 1993;53:503-14.
21. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenet. 1996;6:121-49.
22. Labedzki A, Buters J, Jabrane W, Fuhr U. Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. Biochem Pharmacol. 2002;63:2159-67.
23. Field A. Discovering statistics using IBM SPSS statistics. London: Sage; 2013.
24. Babyak MA. What You See May Not Be What You Get: A Brief, Nontechnical Introduction to Overfitting in Regression-Type Models. Psychosom Med. 2004;66(3):411-21.
25. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51(1):83-133.
26. Chen L, Bondoc FY, Lee MJ, Hussin AH, Thomas PE, Yang CS. Caffeine induces cytochrome P4501A2: induction of CYP1A2 by tea in rats. Drug Metab Dispos. 1996;24:529-33.
27. Goasduff T, Dréano Y, Guillois B, Menez JF, Berthou F. Induction of liver and kidney CYP1A1/1A2 by caffeine in rat. Biochem Pharmacol. 1996;52:1915-9.
28. Landi MT, Zocchetti C, Bernucci I, Kadlubar FF, Tannenbaum S, Skipper P, Bartsch H, Malaveille C, Shields P, Caporaso NE, Vineis P. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomarkers Prev. 1996;5:693-8.
29. Fontana RJ, Lown KS, Paine MF, Fortlage L, Santella RM, Felton JS, Knize MG, Greenberg A, Watkins PB. Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology. 1999;117:89-98.
30. Palatini P, Benetti E, Mos L, Garavelli G, Mazzer A, Cozzio S, Fania C, Casiglia E. Association of coffee consumption and CYP1A2 polymorphism with risk of impaired fasting glucose in hypertensive patients. Eur J Epidemiol. 2015;30(3):209-17.
31. Addicott MA, Yang LL, Peiffer AM, Laurienti PJ. Methodological considerations for the quantification of self-reported caffeine use. Psychopharmacology. 2009;203:571-8.
32. Bracken MB, Triche E, Grosso L, Hellenbrand K, Belanger K, Leaderer BP. Heterogeneity in assessing self-reports of caffeine exposure: implications for studies of health effects. Epidemiology. 2002;13:165-71.